secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001821586-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moonlake reports FY2022 net loss $64.5M; HS trial top-line expected June 2023
-----------------------------------------------------------------------------

- Net loss for year ended Dec 31, 2022 was $64.5M vs $53.6M for prior period (March 2021 to Dec 2021).
- Cash, equivalents and short-term marketable debt securities $72.1M at Dec 31, 2022; runway into 2H 2024.
- Phase 2 HS trial top-line results expected around end of June 2023; final readout by Q4 2023.
- Phase 2 PsA trial enrollment on schedule; top-line results anticipated at end of 2023.
- Capital Markets Day set for April 19, 2023 in New York and via webcast.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/0001821586-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/mnlk-20230320.htm
  HTML page:      https://secwatch.observer/filing/0001821586-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer